A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

NCT03979313 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3012

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: MEDI8897
DRUG: Placebo

Sponsor

AstraZeneca